Wednesday, October 23, 2013

Over $1 billion is to be invested in new biologics production in the US and Europe Genentech, Genzyme and Vetter announce new capital investments



Last week was a good one for construction engineers tracking the biopharma industry. Three significant new capital investments were announced; notably, all three involve biologics, giving more evidence (in case anyone needed it) that the industry is shifting more and more into biotech products.

No comments: